Insider Selling: Jazz Pharmaceuticals (NASDAQ:JAZZ) CAO Sells 4,660 Shares of Stock

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) CAO Patricia Carr sold 4,660 shares of Jazz Pharmaceuticals stock in a transaction dated Friday, December 5th. The shares were sold at an average price of $171.20, for a total transaction of $797,792.00. Following the sale, the chief accounting officer owned 7,012 shares of the company’s stock, valued at $1,200,454.40. The trade was a 39.92% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Patricia Carr also recently made the following trade(s):

• On Tuesday, November 18th, Patricia Carr sold 5,319 shares of Jazz Pharmaceuticals stock. The stock was sold at an average price of $182.06, for a total transaction of $968,377.14.

Jazz Pharmaceuticals Trading Down 4.0%

Shares of NASDAQ:JAZZ traded down $6.68 during trading on Tuesday, reaching $162.26. 1,176,191 shares of the company were exchanged, compared to its average volume of 954,734. The business’s fifty day simple moving average is $148.64 and its 200-day simple moving average is $127.81. The company has a debt-to-equity ratio of 1.09, a current ratio of 1.65 and a quick ratio of 1.44. Jazz Pharmaceuticals PLC has a 12-month low of $95.49 and a 12-month high of $182.99. The firm has a market capitalization of $9.86 billion, a PE ratio of -26.73, a P/E/G ratio of 3.82 and a beta of 0.30.

Analyst Ratings Changes

JAZZ has been the subject of a number of research analyst reports. Royal Bank Of Canada set a $194.00 target price on Jazz Pharmaceuticals and gave the company an “outperform” rating in a research report on Monday, November 17th. Weiss Ratings restated a “sell (d+)” rating on shares of Jazz Pharmaceuticals in a research note on Monday. JPMorgan Chase & Co. decreased their price objective on Jazz Pharmaceuticals from $204.00 to $199.00 and set an “overweight” rating for the company in a report on Monday, October 27th. Bank of America increased their target price on shares of Jazz Pharmaceuticals from $230.00 to $247.00 and gave the stock a “buy” rating in a report on Tuesday, November 18th. Finally, UBS Group reissued a “neutral” rating and set a $188.00 target price (up previously from $163.00) on shares of Jazz Pharmaceuticals in a research report on Monday, November 24th. Thirteen equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $195.67.

Institutional Trading of Jazz Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Farther Finance Advisors LLC boosted its position in shares of Jazz Pharmaceuticals by 754.8% in the 3rd quarter. Farther Finance Advisors LLC now owns 265 shares of the specialty pharmaceutical company’s stock worth $35,000 after purchasing an additional 234 shares in the last quarter. SVB Wealth LLC purchased a new stake in Jazz Pharmaceuticals in the first quarter valued at about $36,000. Hantz Financial Services Inc. boosted its holdings in Jazz Pharmaceuticals by 471.4% in the second quarter. Hantz Financial Services Inc. now owns 360 shares of the specialty pharmaceutical company’s stock worth $38,000 after acquiring an additional 297 shares in the last quarter. Danske Bank A S purchased a new stake in shares of Jazz Pharmaceuticals during the third quarter worth about $40,000. Finally, Quent Capital LLC acquired a new position in shares of Jazz Pharmaceuticals during the third quarter valued at about $44,000. Hedge funds and other institutional investors own 89.14% of the company’s stock.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.